Aspirin + atorvastatin + ramipril

Articles · New Medicines ·

7947003

Articles

New Medicines

Trinomia · Secondary prevention of cardiovascular disease and treatment of hypertension

Information

Trinomia
New formulation
Ferrer

Development and Regulatory status

None
Phase III Clinical Trials
Phase II Clinical Trials

Category

Oral fixed-dose combination of an antiplatelet (aspirin), statin (atorvastatin) and ACE inhibitor (ramipril)
The revised Joint British Societies (JBS 3) guidelines on prevention of cardiovascular disease (CVD) in clinical practice recommend that CVD prevention should focus equally on the following three groups of patients who are at high risk of CVD: Apparently healthy individuals with 20% or greater risk over 10 years of developing symptomatic atherosclerotic disease, people with diabetes mellitus (type 1 or 2), and people with established atherosclerotic CVD [1].
Secondary prevention of cardiovascular disease and treatment of hypertension
Intravitreal